Applied DNA Sciences Inc (APDN): Price and Financial Metrics
APDN Price/Volume Stats
| Current price | $1.44 | 52-week high | $7.35 |
| Prev. close | $1.42 | 52-week low | $0.62 |
| Day low | $1.44 | Volume | 4,076 |
| Day high | $1.44 | Avg. volume | 87,723 |
| 50-day MA | $1.09 | Dividend yield | N/A |
| 200-day MA | $1.56 | Market Cap | 18.59M |
APDN Stock Price Chart Interactive Chart >
APDN POWR Grades
- APDN scores best on the Sentiment dimension, with a Sentiment rank ahead of 81.8% of US stocks.
- The strongest trend for APDN is in Quality, which has been heading up over the past 136 days.
- APDN's current lowest rank is in the Momentum metric (where it is better than 7.23% of US stocks).
APDN Stock Summary
- With a market capitalization of $14,844,798, APPLIED DNA SCIENCES INC has a greater market value than only 6.39% of US stocks.
- The volatility of APPLIED DNA SCIENCES INC's share price is greater than that of 87.69% US stocks with at least 200 days of trading history.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for APDN comes in at -94.54% -- higher than that of only 5.98% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to APPLIED DNA SCIENCES INC, a group of peers worth examining would be IRIX, BIOC, CTS, KRKR, and RPID.
- Visit APDN's SEC page to see the company's official filings. To visit the company's web site, go to www.adnas.com.
APDN Valuation Summary
- In comparison to the median Industrials stock, APDN's EV/EBIT ratio is 103.18% lower, now standing at -0.5.
- APDN's price/sales ratio has moved down 90.8 over the prior 206 months.
Below are key valuation metrics over time for APDN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| APDN | 2023-05-19 | 0.8 | 1.4 | -2.8 | -0.5 |
| APDN | 2023-05-18 | 0.8 | 1.5 | -2.9 | -0.6 |
| APDN | 2023-05-17 | 0.8 | 1.5 | -2.9 | -0.6 |
| APDN | 2023-05-16 | 0.8 | 1.4 | -2.8 | -0.5 |
| APDN | 2023-05-15 | 0.8 | 1.4 | -2.8 | -0.5 |
| APDN | 2023-05-12 | 0.8 | 1.4 | -2.7 | -0.4 |
APDN Growth Metrics
- Its 3 year price growth rate is now at -95.34%.
- Its year over year net income to common stockholders growth rate is now at -5.91%.
- Its year over year cash and equivalents growth rate is now at -52.87%.
The table below shows APDN's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-12-31 | 19.26572 | -7.657918 | -7.499602 |
| 2022-09-30 | 18.16868 | -8.976706 | -8.377996 |
| 2022-06-30 | 17.64909 | -10.43016 | -12.22587 |
| 2022-03-31 | 15.05304 | -9.92572 | -14.55064 |
| 2021-12-31 | 11.5773 | -12.93411 | -14.19865 |
| 2021-09-30 | 9.027738 | -13.38795 | -14.28644 |
APDN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- APDN has a Quality Grade of D, ranking ahead of 5.38% of graded US stocks.
- APDN's asset turnover comes in at 0.427 -- ranking 359th of 563 Business Services stocks.
- GRNQ, VOLT, and FC are the stocks whose asset turnover ratios are most correlated with APDN.
The table below shows APDN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.427 | 0.793 | -5.931 |
| 2021-03-31 | 0.361 | 0.820 | -6.288 |
| 2020-12-31 | 0.252 | 0.749 | -9.825 |
| 2020-09-30 | 0.163 | 0.627 | -10.610 |
| 2020-06-30 | 0.331 | 0.731 | -7.330 |
| 2020-03-31 | 0.683 | 0.796 | -6.300 |
APDN Price Target
For more insight on analysts targets of APDN, see our APDN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $17.67 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Applied DNA Sciences Inc (APDN) Company Bio
Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes applications in the United States, Europe, and Asia. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications and can be used to fortify brand protection efforts, and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide definitive real-time authentication of molecular tags in the field; and CertainT Supply Chain Platform that provides proof of product claims for materials, items, or products. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and non-diagnostic COVID-19 pooled surveillance testing to detect instances of COVID-19 in defined populations under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
Latest APDN News From Around the Web
Below are the latest news stories about APPLIED DNA SCIENCES INC that investors may wish to consider to help them evaluate APDN as an investment opportunity.
Applied DNA Sciences, Inc. (NASDAQ:APDN) Q2 2023 Earnings Call TranscriptApplied DNA Sciences, Inc. (NASDAQ:APDN) Q2 2023 Earnings Call Transcript May 11, 2023 Applied DNA Sciences, Inc. beats earnings expectations. Reported EPS is $0.05, expectations were $-0.2. Operator: Hello and welcome to the Applied DNA Sciences Fiscal Second Quarter 2023 Financial Results. All parties will be in listen-only mode. [Operator Instructions]. Please note today’s event […] |
Applied DNA Reports Second Quarter Fiscal 2023 Financial Results and Provides Corporate UpdateApplied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for the second quarter of fiscal 2023 ended March 31, 2023. |
Applied DNA to Report Second Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, May 11, 2023STONY BROOK, N.Y., May 03, 2023--Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release financial results for the three months ended March 31, 2023 after the market close on Thursday, May 11, 2023. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. ET. |
Applied DNA's CertainT® Supply Chain Traceability Platform Featured in New York Times Article About the Need for Transparency and Compliance in Global Supply Chains Under Recently Passed U.S. Federal RegulationSTONY BROOK, N.Y., April 07, 2023--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the "Company"), a leader in PCR-based DNA technologies, announced that its CertainT® supply chain traceability platform is featured in an article on the home page of the New York Times website today. The article, titled "How A.I. and DNA Are Unlocking the Mysteries of Global Supply Chains," centers on the mounting need for the textile and other industries to employ tracing technologies to ensure compliance with the Uyg |
Applied DNA Achieves Milestone for Large-Scale linearDNA™ Production, Delivers Largest Single Shipment by Volume to DateSTONY BROOK, N.Y., March 29, 2023--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the "Company"), a leader in PCR-based DNA technologies, today announced that it has established a new high bar for the production of DNA with the manufacture and shipment of a multi-gram quantity of linearDNA™ in under six weeks. The quantity was produced by the Company’s LinearDNA™ platform under a large recurring purchase order with a global manufacturer of in vitro diagnostics that was announced in the first quarter |
APDN Price Returns
| 1-mo | 39.13% |
| 3-mo | 18.03% |
| 6-mo | 3.60% |
| 1-year | 30.91% |
| 3-year | -80.43% |
| 5-year | -97.43% |
| YTD | -13.25% |
| 2022 | -58.71% |
| 2021 | -21.18% |
| 2020 | 21.72% |
| 2019 | -73.81% |
| 2018 | -74.84% |
Continue Researching APDN
Want to see what other sources are saying about Applied Dna Sciences Inc's financials and stock price? Try the links below:Applied Dna Sciences Inc (APDN) Stock Price | Nasdaq
Applied Dna Sciences Inc (APDN) Stock Quote, History and News - Yahoo Finance
Applied Dna Sciences Inc (APDN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...